# Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma

> **NCT00077584** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 188 (actual)

## Conditions studied

- Digital Ulcers
- Systemic Sclerosis

## Interventions

- **DRUG:** Bosentan 62.5 mg
- **DRUG:** Bosentan 125 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00077584
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2005-03
- **Final completion:** 2005-05
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077584, "Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00077584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*